Premium
Dose‐response relationship for mivacurium inpatients with phenotypically abnormal plasma cholinesterase activity
Author(s) -
OSTERGAARD D.,
JENSEN F. S.,
SKOVGAARD L. THEIL,
VIBYMOGENSEN J.
Publication year - 1995
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1995.tb04220.x
Subject(s) - medicine , cholinesterase , anesthesia , fentanyl , nitrous oxide , pharmacology , endocrinology
During thiopentone‐fentanyl‐nitrous oxide anaesthesia and using a cumulative design, we studied the dose‐response relationship of mivacurium in 8 patients: 7 patients phenotypically homozygous for the atypical plasma cholinesterase gene and 1 patient homozygous for the silent gene. The estimated mean ED 50 and ED 95 were 15 and 20 μg. kg. bw ‐1 in patients homozygous for the atypical gene, and 13 and 16 μg. kg. bw ‐1 in the patient homozygous for the silent gene, respectively. The results indicate that mivacurium is 4‐5 times more potent in patients homozygous for the atypical or the silent gene than in patients with normal plasma cholinesterase activity and phenotype.